Last reviewed · How we verify
CoFactor (ANX-510)
CoFactor (ANX-510) is a cofactor replacement therapy designed to restore deficient cofactor levels in patients with certain metabolic or genetic disorders.
CoFactor (ANX-510) is a cofactor replacement therapy designed to restore deficient cofactor levels in patients with certain metabolic or genetic disorders. Used for Rare metabolic or genetic disorders associated with cofactor deficiency (specific indication not publicly detailed).
At a glance
| Generic name | CoFactor (ANX-510) |
|---|---|
| Sponsor | Mast Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Rare Genetic/Metabolic Disorders |
| Phase | Phase 3 |
Mechanism of action
ANX-510 functions as a replacement for endogenous cofactors that are depleted or deficient in specific disease states, thereby restoring enzymatic function and metabolic pathways. This approach addresses the underlying biochemical defect rather than symptomatically treating disease manifestations. The drug is intended for conditions where cofactor deficiency is a primary pathogenic mechanism.
Approved indications
- Rare metabolic or genetic disorders associated with cofactor deficiency (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- PQQ for Cognitive and Negative Symptoms (NA)
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia (PHASE1)
- Von Willebrand Factor in Pregnancy (VIP) Study
- Version Testing of EnzySystem Version A for Hemophilia A
- A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma (PHASE1)
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
- Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoFactor (ANX-510) CI brief — competitive landscape report
- CoFactor (ANX-510) updates RSS · CI watch RSS
- Mast Therapeutics, Inc. portfolio CI